PRO
9 min read
Prostate Disorders – Causes, Symptoms, Treatment
1 photo
562
Smart Voice
AI
0:00
0:00
Listen to the article content live
Table of Contents 11
PRO Content
PRO
This article is professional premium content (PRO) provided in its entirety.
Despite the small size of the prostate, the disorders that affect its functioning are a serious health hazard for every man. Abnormalities regarding the condition and function of the prostate are not only a significant source of discomfort, but also a significant health risk. How can prostate diseases be prevented and treated? How can disorders within this gland be identified? What are the most common diseases of the prostate?
01 / 11
The prostate gland: Anatomical structure, location, and physiological role in the male body
This article provides an exhaustive examination of the prostate gland—an exclusive male anatomical structure also referred to as the prostate—a specialized organ present solely in biological males. The discussion meticulously outlines its precise anatomical positioning within the pelvic cavity, where it is situated immediately inferior to the urinary bladder and anteriorly adjacent to the rectal wall, with the proximal segment of the urethra traversing centrally through its substance. The text elaborates extensively on the histological composition of the prostate, distinguishing three fundamental tissue categories: the muscular components governing contractile function, the glandular tissue responsible for secretory activity, and the fibrous stroma serving as structural scaffolding. Standard dimensional parameters for this organ typically approximate 4 × 3.5 × 3.5 centimeters, with an average mass of roughly 11 grams and a volumetric capacity ranging between 25 and 28 milliliters. Additionally, the article addresses the diagnostically critical biomarker—prostate-specific antigen (PSA) concentration—whose reference intervals for men around fifty years of age generally fall within 2–4 nanograms per milliliter, noting that these values undergo physiological adjustments correlated with advancing age.
02 / 11
What Is the Prostate Responsible For? Physiological Functions and Role in Fertility
The prostate gland is responsible for synthesizing and secreting a milky, turbid fluid characterized by a distinct aroma and whitish hue. Prostatic secretions are composed of proteins, zinc, simple carbohydrates, and enzymes, among which prostate-specific antigen (PSA) is clinically predominant. The fluid generated by the prostate plays an indispensable role in male reproduction: its biochemical components provide vital nourishment and mobility support for spermatozoa within the semen, facilitating their journey toward and fertilization of the female ovum. Consequently, prostatic dysfunctions have a profound and direct impact on male fertility and reproductive well-being.
03 / 11
Pathological conditions of the prostate gland: causative mechanisms and categorization of predominant disease entities
Prostatic dysfunction presents with diverse clinical manifestations, yet from a diagnostic and therapeutic standpoint, three primary pathological categories of this gland are systematically distinguished. These include:
• benign hyperplasia of glandular tissue (commonly referred to as prostatic enlargement or benign prostatic hypertrophy),
• inflammatory conditions of varied etiology (encompassing both acute and chronic prostatitis),
• malignant neoplastic transformations, specifically prostate adenocarcinoma (prostate cancer).
04 / 11
Benign prostatic hyperplasia: Etiology, symptomatic manifestations, and preventive strategies for prostate gland enlargement
Benign prostatic hyperplasia, commonly abbreviated as BPH and colloquially referred to as prostate gland enlargement, represents a prevalent age-associated condition among middle-aged and elderly men, marked by the gradual volumetric expansion of the prostate. The primary etiologic determinant is the organism’s inherent aging process, though endocrine shifts—particularly those involving androgen metabolism—also contribute significantly to its pathogenesis. Initial clinical manifestations, such as lower urinary tract symptoms, may emerge as early as the fifth decade of life, with symptom severity typically escalating in subsequent years. While the physiological remodeling of the prostate is an inevitable consequence of aging, proactive lifestyle modifications—including adherence to a nutrient-rich diet, consistent physical exercise, and abstinence from tobacco and alcohol—coupled with routine prophylactic screenings (advised commencing at age 35) can substantially mitigate disease progression and alleviate associated morbidities.
05 / 11
Prostatic inflammation: causative factors, risk determinants, and pathogenic mechanisms of infection
The anatomical positioning of the prostate gland facilitates the ascent of intestinal microbiota—most notably *Escherichia coli*—from the perianal and perineal regions toward the urethra, potentially precipitating urinary tract infections and secondary inflammatory responses within the prostate itself. Nevertheless, the pathogenesis of prostatic inflammation is multifaceted and encompasses additional key determinants:
– **benign prostatic hyperplasia (BPH)**, which obstructs urinary outflow and creates an environment conducive to microbial colonization,
– **urinary catheterization requirements**, significantly elevating the risk of ascending bacterial infection,
– **invasive diagnostic or therapeutic interventions**, such as prostate biopsy procedures, which may inadvertently introduce pathogens into the tissue,
– **prolonged physical inactivity and sedentary behavior** (e.g., desk-bound occupations), leading to pelvic venous congestion,
– **mechanical trauma** (including spinal cord injuries), which disrupts the neural supply to pelvic organs and predisposes to urogenital dysfunction,
– **sexually transmitted infections** (e.g., chlamydia, gonorrhea) and **concurrent urological conditions**, such as nephrolithiasis or urinary incontinence, which impose additional stress on the excretory system.
06 / 11
Malignant neoplasm of the prostate gland: Epidemiological trends, risk determinants, and clinical presentation
Prostatic malignancy represents one of the most prevalent oncological conditions affecting the male population, though the precise etiopathogenesis of this disease process remains an active subject of scientific inquiry. The development of neoplastic alterations within the prostate gland typically arises from the cumulative impact of multiple adverse factors, among which the most prominent include: advanced biological age (particularly in patients surpassing the threshold of 65 years), an improperly balanced diet characterized by excessive intake of saturated fatty acids and highly processed foods coupled with a deficiency in plant-based components (including vegetables, fruits, and whole-grain products), a sedentary lifestyle conducive to obesity development, and a genetic predisposition manifested through familial cancer histories, especially among first-degree relatives.
07 / 11
Clinical manifestations and characteristic symptoms of prostatic gland disorders
Despite the diversity of conditions affecting the prostate gland, there exists a range of recurrent, shared symptoms that accompany most pathologies of this organ. Primarily, an enlargement of the prostate volume leads to mechanical compression of the urinary bladder and urethra, thereby triggering a cascade of dysfunctions within the urinary system. Patients with prostate hyperplasia commonly experience difficulties with proper urination, including weakened urine stream (hypostenuria), frequent nighttime urination (nocturia), pain during micturition, a sensation of incomplete bladder emptying, prolonged voiding time, and challenges initiating urination. Furthermore, vascular disturbances in the prostate and adjacent structures may result in sexual dysfunction, such as erectile difficulties or reduced libido. Pain symptoms are frequently localized in the lumbar spine, perineum, and pubic symphysis. Beyond subjective complaints, prostate disorders are associated with laboratory abnormalities, notably elevated prostate-specific antigen (PSA) levels and decreased testosterone concentrations. Similar symptoms also manifest in prostatitis, though this condition is further characterized by systemic signs such as fever, chills, myalgia, nausea, or vomiting. Prostatitis may present in an acute form (with sudden onset and intense symptoms) or chronically (with gradual progression and milder symptoms, absent of fever). All aforementioned symptoms may also occur in prostate cancer, which is the most perilous condition of the prostate due to its asymptomatic nature in early stages. This malignancy can develop over years without causing visible structural changes in the gland, with a significantly elevated PSA often being the sole early indicator. In advanced cases, prostate cancer may present with bone pain, particularly in the sacrum, proximal femurs, and lumbar spine, which can be mistakenly attributed to degenerative changes, especially in men over 50 years of age.
08 / 11
Comprehensive diagnostic evaluation of prostatic disorders: methodologies for assessing and identifying pathological conditions of the prostate gland
A suite of specialized diagnostic procedures designed to detect and differentiate disorders associated with the prostate gland, encompassing:
• **Microbiological urinalysis** aimed at identifying potential urinary tract infections.
• **Quantitative assessment of free and total testosterone levels** in blood as part of endocrine evaluation.
• **Invasive tissue sampling of the prostate (biopsy)** followed by **meticulous histopathological examination** to detect malignant cells or inflammatory conditions.
• **Digital rectal examination (DRE)**, enabling preliminary assessment of glandular consistency, symmetry, and potential enlargement.
• **Biochemical measurement of the tumor marker PSA** (prostate-specific antigen) in blood, critical for monitoring prostate cancer risk.
• **Advanced imaging modalities**, including **transabdominal ultrasonography**, **pelvic computed tomography (CT)**, and **contrast-enhanced magnetic resonance imaging (MRI)**, facilitating visualization of anatomical structures and detection of abnormalities.
• **Functional uroflowmetry testing**, quantifying voiding parameters (flow rate, micturition time, post-void residual volume) to evaluate subvesical obstructions.
• **Isotope-based bone scintigraphy**, employed to detect metastatic bone lesions and assess metabolic activity within the skeletal system in the context of systemic diseases.
09 / 11
Therapeutic approaches for prostate-related disorders – a comprehensive review of available treatment modalities
The therapeutic approach is strictly contingent upon the underlying etiology of the condition. In instances of benign prostatic hyperplasia (BPH), pharmacological intervention typically involves two primary classes of medications: **selective α1-adrenoceptor antagonists** (such as tamsulosin), which function by alleviating smooth muscle tension in the bladder neck region and prostatic tissue, thereby mitigating obstructive symptomatology; and **5-α-reductase inhibitors** (including dutasteride or finasteride), which inhibit the conversion of testosterone to its potent metabolite, dihydrotestosterone (DHT), thereby reducing prostatic volume. When the condition stems from acute or chronic bacterial inflammation, targeted antibiotic therapy becomes imperative, with the regimen tailored based on urine culture and antibiogram results. First-line agents typically include fluoroquinolones such as ciprofloxacin, owing to their broad-spectrum antibacterial efficacy and favorable tissue penetration into the prostate. In the context of malignant prostatic disease, the treatment paradigm is dictated by the stage of cancer (assessed via Gleason scoring and TNM classification), the presence of distant metastases, and the patient’s overall clinical status. Available modalities include: **radiation therapy** (encompassing brachytherapy with radioactive seed implants), **systemic chemotherapy** (employing docetaxel or cabazitaxel in resistant cases), **immunotherapy** (e.g., sipuleucel-T vaccine), **hormonal therapy** (achieved via androgen deprivation using LHRH agonists/antagonists or androgen synthesis inhibitors), and **surgical intervention**, notably radical prostatectomy—particularly in locally advanced or high-risk progression scenarios.
10 / 11
Herbal support in prostate therapy – the significance of phytotherapy in maintaining prostate health
Maintaining optimal urogenital system function serves as the cornerstone for both the prevention and treatment of prostate disorders. In this regard, supplementation with natural ingredients—primarily plant extracts and trace minerals—plays a pivotal role. It is crucial to emphasize, however, that these supplements must not be regarded as the primary therapeutic intervention; rather, they function as a complementary component within a broader spectrum of preventive measures. These include a balanced diet, regular physical exercise, weight management, and the elimination or substantial reduction of stimulants such as alcohol and tobacco products. Among the most valuable dietary components, pumpkin—particularly its seeds and derived oil—holds a position of distinction. These contain unique plant sterols (including Δ-7-sterols), which are attributed with the capacity to modulate dihydrotestosterone (DHT) levels. Additionally, pumpkin seeds and oil are abundant in compounds exhibiting potent antioxidant properties, such as squalene, phenolic acids, carotenoids, and tocotrienols. The presence of cucurbitacin—a substance with antiparasitic effects—further enhances its role in combating urinary tract infections. Pumpkin also provides significant quantities of selenium (essential for immune function, spermatogenesis, and protection against oxidative stress) and zinc (critical for male fertility and the maintenance of physiological testosterone levels). Another exceptionally valuable ingredient is garlic, whose active compound, allicin, metabolizes into other bioactive sulfur derivatives such as ajoene, DAS, and DADS. These compounds demonstrate promising properties in oncology, including the inhibition of cell cycle progression and the induction of apoptosis in cancerous cells. Additional plants of potential significance for prostate health include: small-flowered willow herb (which may contribute to lowering PSA levels), nettle (acting as a diuretic to support normal urination and urinary tract function), saw palmetto (which inhibits the conversion of testosterone to DHT), and African plum (a source of phytosterols with anti-DHT effects that promote prostate epithelial regeneration, reduce urethral tension, and alleviate prostatic inflammation).
11 / 11
The significance of balanced nutrition and consistent physical exercise in sustaining optimal prostate gland function
It is essential to emphasize that a well-balanced diet constitutes a cornerstone of both preventive and therapeutic strategies concerning prostate gland disorders. Excess body weight—particularly abdominal obesity—and associated lipid metabolism disturbances, most notably elevated low-density lipoprotein (LDL) cholesterol, are well-documented risk factors for the development of prostatic pathologies. Dietary guidelines strongly advise reducing the intake of high-fat animal-derived products, such as whole-fat dairy, fatty cheeses, and red meat, in favor of leaner alternatives; ideally, consumption of lean meats (e.g., skinless poultry or low-fat fish) should not exceed three servings per week. Of paramount importance is the enrichment of one’s diet with plant-based foods rich in high-quality protein and dietary fiber, the latter of which promotes intestinal motility and facilitates toxin elimination. Equally indispensable are sources of polyunsaturated omega-3, -6, and -9 fatty acids, found in oily marine fish (e.g., salmon, mackerel, sardines), flaxseed oil, walnuts, and chia seeds. The antioxidant properties of deeply pigmented fruits—such as chokeberry, blackcurrant, pomegranate, raspberries, or açaí—play a critical role in counteracting the deleterious effects of reactive oxygen species. Concurrently, regular moderate-intensity physical activity (e.g., brisk walking, swimming, cycling) not only aids in maintaining a healthy weight but also enhances immune function, optimizes hormonal balance (including testosterone levels), and mitigates oxidative stress by improving microcirculation and detoxification processes within the body.
Meal Plan
Want to apply these guidelines in your daily diet?
Our smart diet generator creates a tailored meal plan in 3 minutes based on the recommendations in this article.
Tags
Scientifically reviewed by a clinical dietitian
• 25.09.2026
Antoniewska A. et al., Olej z nasion dyni jako źródło cennych składników w diecie człowieka, „Problemy Higieny i Epidemiologii” 2017, 98(1), 17–22. Bonn S.E. et al., Physical Activity and Survival among Men Diagnosed with Prostate Cancer, „Cancer Epidemiology, Biomarkers & Prevention” 2015, 24(1), 57–64. Borówka A., Łagodny rozrost stercza: etiologia, patofizjologia, leczenie farmakologiczne, „Nowa Klinika” 2000, 7(5), 518–524. Cieśliński P., Dadej R., Kwias Z., Rak stercza, „Współczesna Onkologia” 2002, 6(2), 108–116. Cristoni A., Di Pierro F., Bombardelli E., Botanical derivatives for the prostate, „Fitoterapia” 2000, 71(suppl. 1), 21–28. Dadej R., Jędrzejczak-Dadej A., Zapalenie gruczołu krokowego, „Geriatria” 2008, 2, 247–251. Edwards J.L., Diagnosis and Management of Benign Prostatic Hyperplasia, „American Family Physician” 2008, 77(10), 1403–1410. Ejchman W., BPH – fitoterapia. Zalety i działania niepożądane, „Przegląd Urologiczny” 2004, 1(23), 26–27. Gryszczyńska A., Opala B., Palma sabałowa (Sabal palmetto Lodd., Saw palmetto) w łagodnym rozroście gruczołu krokowego, „Postępy Fitoterapii” 2011, 1, 18–27. Hurkacz M., Czy stosowanie fitoterapi w leczeniu łagodnego rozrostu prostaty jest skuteczne i bezpieczne?, „Przegląd Urologiczny” 2014, 4(62), 38–40. Jereczek-Fossa B.A., Rola radioterapii w leczeniu raka gruczołu krokowego, „Współczesna Onkologia” 2003, 7(3), 176–182. Krieger J.N. et al., Epidemiology of prostatitis, „International Journal of Antimicrobial Agents” 2008, 31(suppl. 1), 85–90. Kromołowska R., Wołosiak R., Sadowska A., Naturalne substancje o działaniu antykancerogennym w żywności, „Postępy Techniki Przetwórstwa Spożywczego” 2011, 1, 87–91. Medjakovic S. et al., Pumpkin seed extract: Cell growth inhibition of hyperplastic and cancer cells, independent of steroid hormone receptors, „Fitoterapia” 2016, 110, 150–156. Merriel S.W.D., Funston G., Hamilton W., Prostate Cancer in Primary Care, „Advances in Therapy” 2018, 35(9), 1285–1294. Nawrot J., Surowce roślinne stosowane w łagodnym przeroście gruczołu krokowego, „Herba Polonica” 2009, 55(4), 214–223. Patel A.R., Klein E.A., Risk factors for prostate cancer, „Nature Clinical Practice Urology” 2009, 6(2), 87–95. Senkus-Konefka E., Jassem J., Wełnicka-Jaśkiewicz M., Rola hormonoterapii u chorych na raka gruczołu krokowego, „Współczesna Onkologia” 2003, 7(3), 198–205. Sierżantowicz R. et al., Ocena wiedzy pacjentów na temat łagodnego rozrostu gruczołu krokowego, „Problemy Pielęgniarstwa” 2009, 17(3), 223–227. Sikora-Kupis B., Rak gruczołu krokowego, „Onkologia w Praktyce Klinicznej – Edukacja” 2019, 5(suppl. H), 9–11. Steenkamp V., Phytomedicines for the prostate, „Fitoterapia” 2003, 74(6), 545–552. Szczęch R., Narkiewicz K., Łagodny rozrost prostaty, „Choroby Serca i Naczyń” 2009, 6(1), 47–48. Szkarłat K., Prostatitis – zapalenie gruczołu krokowego, „Przegląd Urologiczny” 2007, 5(45), 34–39. Twardak I.M. et al., Rola diety w rozwoju raka prostaty, „Pielęgniarstwo i Zdrowie Publiczne” 2015, 5(4), 417–425. Wardecki D., Dołowy M., Rak prostaty – aktualne możliwości terapeutyczne, „Farmacja Polska” 2022, 78(5), 268–276. Zalega J., Szostak-Węgierek D., Żywienie w profilaktyce nowotworów. Część III. Diety o właściwościach przeciwnowotworowych, „Problemy Higieny i Epidemiologii” 2013, 94(1), 59–70. Ząbkowski T., Bortnowski L., Profilaktyka, monitorowanie i leczenie raka gruczołu krokowego na podstawie aktualnego przeglądu literatury urologicznej, „Pediatria i Medycyna Rodzinna” 2008, 4(4), 265–268.
Diets Premium Expert
Diets Premium team expert. Specializes in nutrition plans, strength sports, and training plans.
USDA FoodData Central
EFSA
PubMed Clinical Guidelines
